Virtual Library

Start Your Search

Zulfiya Syunyaeva



Author of

  • +

    P1.01 - Advanced NSCLC (ID 158)

    • Event: WCLC 2019
    • Type: Poster Viewing in the Exhibit Hall
    • Track: Advanced NSCLC
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/08/2019, 09:45 - 18:00, Exhibit Hall
    • +

      P1.01-17 - Changes in Pulmonary Function During Platinum-Doublet Chemotherapy for Lung Cancer (ID 2281)

      09:45 - 18:00  |  Author(s): Zulfiya Syunyaeva

      • Abstract
      • Slides

      Background

      Lung cancer treatments, including checkpoint inhibitors, tyrosine kinase inhibitors, chemotherapy and multimodal treatments, may cause pulmonary side effects. Clinical trials document pulmonary toxicity but rarely include mandatory serial pulmonary function testing. As such, little is known about the changes in pulmonary function during systemic treatments, in particular in patients without manifest pulmonary toxicity. We present a longitudinal analysis of platinum-based chemotherapy for lung cancer and examine the effect of different chemotherapies on pulmonary function.

      Method

      We retrospectively analyzed lung cancer patients treated with platinum-doublets and correlated lung function (FEV1, vital capacity, total lung capacity and diffusion) changes with the type of chemotherapy received.

      Result

      We included 838 patients at the Munich Lung Cancer Centre from January 2013 until April 2019. The average patient age was 66,8 ± 9,79 years. 510 patients were male (60,9%). Histology was as follows: 410 adenocarcinoma, 153 small cell neuroendocrine carcinoma, 147 squamous cell carcinoma and 128 cases with other histologies. Platin was paired with pemetrexed (n=279), vinorelbine (n=205), etoposide (n=190), taxanes (docetaxel, paclitaxel, nab-paclitaxel; n=93) or gemcitabine (n=53). Lung function tests performed before and after chemotherapy were analyzed. During treatment, lung function parameters often improved. Pneumonitis was rare. There were chemotherapy-subgroup differences in lung function during treatment.

      Conclusion

      Platinum doublets are associated with clinically relevant changes in lung function. Pneumonitis during chemotherapy is rare, and many patients experience improvements in pulmonary function during chemotherapy. The choice of chemotherapeutic agents may affect pulmonary outcomes. Larger studies of the effect of individual chemotherapeutic agents on pulmonary function in this setting and combined with immunotherapies are warranted.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    P2.01 - Advanced NSCLC (ID 159)

    • Event: WCLC 2019
    • Type: Poster Viewing in the Exhibit Hall
    • Track: Advanced NSCLC
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
    • +

      P2.01-43 - Pre-Therapeutic Markers and Scores Predict Response and Survival in Stage IV Lung Cancer Patients Independent of Histology (ID 2992)

      10:15 - 18:15  |  Author(s): Zulfiya Syunyaeva

      • Abstract

      Background

      Lung cancer is the leading cause of death among all cancer entities. Identification of reliable and validated predictive and prognostic markers is important to estimate patients’ prognosis. By doing this, planning of treatment and adequate patient guidance would improve. Many studies investigated several predictive and prognostic markers in lung cancer patients. Never the less, most of them describe very selective cohorts. This study aims at investigating histology independent predictive and prognostic markers in stage IV lung cancer patients.

      Method

      We retrospectively analyzed 129 stage IV lung cancer patients who had been diagnosed and treated at a German tertiary care lung cancer center between 2015 and 2016. Patients’ characteristics in terms of age, gender, performance status, histology, smoking status, treatment modalities and molecular pathological findings were collected from patients’ charts. We extracted data sets from electronic patient records and compared anthropometric data, pre-therapeutic blood values as well as clinical scores and performed tests for prediction analysis

      Result

      Eight markers and scores could be identified to significantly alter prognosis in univariate analysis. Over the normal cut off elevated values of CRP (p < 0.001), LDH (p < 0.001), Neutrophil to Lymphocyte ratio (NLR) (p = 0.018) and Systemic Inflammation Index (SII) (p = 0.036) as well as decreased levels of MCV (p = 0.025) and total protein (p = 0.049) were significantly associated with reduced overall survival (OS). Furthermore, the higher the Glasgow Prognostic Score (GPS) (p < 0.001) or the Lung Prognostic Index (PI-lung) (p < 0.001) were the worse was the OS.

      Failure of first line treatment was significantly predicted by low albumin (p=0.006), lymphocytes (p = 0.032) and PNI (p = 0.001) levels, whereas low values of CRP (p < 0.001), LDH (p = 0.042) and Thrombocyte to Lymphocyte ration (TLR) (p = 0.017) predict response to first line therapy. Multivariate analysis revealed CRP, PI-lung and GPS as independent prognostic factors regardless histology.

      Conclusion

      Simply to obtain blood values and clinical scores provide histology independent markers for response to fist line treatment and survival in stage IV lung cancer patients.